Pure Global
NCT02414685

First Line TIP in Poor Prognosis TGCTs.

A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.
National Cancer Institute, Slovakia·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
Paclitaxel
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Cancer Institute, Slovakia
Location
Bratislava, Slovakia
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2015
End date
Jun 01, 2020
Enrollment
19 participants
Primary outcome

Complete response rate

Summary

TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor
 markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until
 progression, unacceptable toxicity, complete response or inability of the subject to comply
 with study requirements.

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02414685
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02414685 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Institute, Slovakia and is currently Completed. The study focuses on Germ Cell Tumor. Target enrollment is 19 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.